key: cord-0273662-x2tevn8i
authors: Hilterbrand, Adam T.; Daly, Raecliffe E.; Heldwein, Ekaterina E.
title: Contributions of the four essential entry glycoproteins to HSV-1 tropism and the selection of entry routes
date: 2021-01-18
journal: bioRxiv
DOI: 10.1101/2020.03.10.985325
sha: 796d4c5a05fc2b06826277f1b37b804c3bc3834d
doc_id: 273662
cord_uid: x2tevn8i

Herpes Simplex viruses (HSV-1 and HSV-2) encode up to 16 envelope proteins, four of which are essential for entry. However, whether these four proteins alone are sufficient to dictate the broad cellular tropism of HSV-1 and the selection of different cell-type dependent entry routes is unknown. To begin addressing this, we previously pseudotyped VSV, lacking its native glycoprotein G, with only the four essential entry glycoproteins of HSV-1: gB, gH, gL, and gD. This novel VSVΔG-BHLD pseudotype recapitulated several important features of HSV-1 entry: the requirement for gB, gH, gL, gD, a cellular receptor, and sensitivity to anti-gB and anti-gH/gL neutralizing antibodies. However, due to the use of a single cell type in that study, the tropism of the VSVΔG-BHLD pseudotype was not investigated. Here, we show that the cellular tropism of the pseudotype is severely limited compared to wild-type HSV-1 and that its entry pathways differ from the native HSV-1 entry pathways. To test the hypothesis that other HSV-1 envelope proteins may contribute to HSV-1 tropism, we generated a derivative pseudotype containing the HSV-1 glycoprotein gC (VSVΔG-BHLD-gC) and observed a gC-dependent increase in entry efficiency in two cell types. We propose that the pseudotyping platform developed here has the potential to uncover functional contributions of HSV-1 envelope proteins to entry in a gain-of-function manner. Importance Herpes simplex viruses (HSV-1 and HSV-2) contain up to 16 different proteins in their envelopes. Four of these, glycoproteins gB, gD, gH, and gL, are termed essential with regard to entry whereas the rest are typically referred to as non-essential based on the entry phenotypes of the respective single genetic deletions. However, the single-gene deletion approach, which relies on robust loss-of-function phenotypes, may be confounded by functional redundancies among the many HSV-1 envelope proteins. We have developed a pseudotyping platform, in which the essential four entry glycoproteins are isolated from the rest, which can be added back individually for systematic gain-of-function entry experiments. Here, we show the utility of this platform for dissecting the contributions of HSV envelope proteins, both the essential four and the remaining dozen (using gC as an example), to HSV entry.

Herpes simplex viruses (HSV-1 and HSV-2) are enveloped viruses that infect much of the 48 world's population for life and cause diseases ranging from painful oral or genital lesions to 49 serious conditions such as encephalitis and blindness (1, 2). These viruses enter target cells by 50 different, cell-type specific routes. For example, they enter neurons by direct fusion of their 51 envelopes with the plasma membrane (3) and epithelial cells by endocytosis followed by fusion 52 with an endosomal membrane (4, 5). While these entry pathways have been broadly described, 53 the underlying mechanisms and the contributions of individual viral and cellular proteins to the 54 selection of these entry routes remain incomplete. 55 HSV-1 entry by any route requires the coordinated efforts of four glycoproteins -gB, gH, 56 gL, and gD, which are essential for entry (6-8) -and a cellular gD receptor (3, 9, 10) . gB, gH, 57 gL, and gD are also sufficient for cell-cell fusion of uninfected receptor-bearing cells expressing 58 these four glycoproteins (11, 12) . The prevalent model, which was largely developed through 59 studies using the cell-cell fusion system, posits that these four viral glycoproteins orchestrate 60 membrane fusion through a sequential activation process termed a cascade (13, 14) . First, gD 61 binds one of its three cellular receptors, nectin-1, herpesvirus entry mediator (HVEM), or 3-O-62 12 filamentous actin is essential for the formation of membrane ruffles and subsequent uptake 244 during macropinocytosis (71). Actin polymerization is, thus, a major hallmark of 245 macropinocytosis (68). Accordingly, we did not observe any appreciable co-localization of 246 VSVDG-BHLD virions with the 70-kDa rhodamine B labeled dextran, a fluid phase uptake 247 marker (Figs. S5 and S6) . Collectively, these results suggest that neither VSVDG-BHLD nor 248 HSV-1 utilize macropinocytosis for entry into C10 or CHO-HVEM cells. However, NHE and 249 Rac1 facilitate VSVDG-BHLD entry into both cell lines, presumably, independently of their role 250 in macropinocytosis. 251

Although VSV enters cells by CME rather than macropinocytosis, it has been shown to 252 require filamentous actin to achieve full engulfment of the viral particle by the plasma membrane 253 during endocytosis, as observed in BSC-1 cells, an African green monkey epithelial cell line (58, 254 72) . Indeed, VSVDG-G entry into C10 cells was modestly reduced by cytochalasin D and EIPA 255 but not NSC23766 (Fig. S7A ) whereas its entry into CHO-HVEM cells was somewhat reduced 256 by EIPA but not cytochalasin D or NSC23766 (Fig. S7C) . The apparent lack of actin 257 involvement in VSVDG-G entry into CHO-HVEM cells may represent a cell-type specific 258 phenomenon. VSVDG-PIV5 entry was not blocked with any of the three inhibitors of 259 macropinocytosis, consistent with fusion at the plasma membrane, and was, in fact, increased in 260 the presence of EIPA in C10 cells (Fig. S7B) . 261 262

Endocytic 263 entry by many viruses requires small GTPases known as Rabs. Rab GTPases are important for 264 the formation of endosomal compartments in the cell (73). Different viruses penetrate endocytic 265 membranes at distinct endosomal maturation stages -for example, VSV fuses with membranes 266

As expected, entry of VSVDG-G into both C10 and CHO-HVEM cells was reduced in 289 the presence of Rab5DN (Figs. S8A and E) , in accordance with reports of VSV fusing with 290 membranes of early endosomes (52). VSVDG-PIV5 entry into C10 cells was insensitive to 291 Rab5DN or Rab7DN (Fig. S8C) . Although VSVDG-PIV5 entry into CHO-HVEM cells was 292 reduced by Rab5DN and Rab7DN in a statistically significant manner, the differences were 293 relatively small (Fig. S8G ). This suggested that Rab5DN and Rab7DN have a minimal effect on 294 VSVDG-PIV5 entry as expected for a virus that fuses with the plasma membrane. 295

Another small GTPase, ADP-ribosylation factor 6 (Arf6), which is involved in regulating 296 vesicular trafficking (79), regulates the endocytic entry of HIV, Coxsackievirus, . To probe the role of Arf6 in entry, cells were treated with NAV-2729, which 298 blocks Arf6 interaction with guanine exchange factors (GEFs) thereby preventing its activation 299 (83). HSV-1 entry into both C10 and CHO-HVEM cells was inhibited by NAV-2729 (Figs. 6B 300 and F) whereas VSVDG-BHLD entry was not (Figs. 6D and H) , which suggests that only HSV-1 301 entry requires Arf6 activity. 302 VSVDG-PIV5 entry was not inhibited by NAV-2729 in either C10 or CHO-HVEM cells 303 (Figs. S8D and H) . However, VSVDG-G entry was inhibited by NAV-2729 in both C10 and 304 CHO-HVEM cells, suggesting that Arf6 could be involved in VSV endocytosis (Figs S8B and 305 F). These results point to a previously unappreciated role of Arf6 in HSV-1 and VSV entry. 306 307

manner. To investigate the role of endosomal acidification in entry, we used three common 309 inhibitors, NH 4 Cl, a weak base; monensin, a carboxylic ionophore; and bafilomycin A1 (BFLA), 310 an endosomal V-ATPase inhibitor. Each inhibitor effectively blocked endosomal acidification as 311 evidenced by decrease in Lysotracker fluorescence in inhibitor-treated cells (Fig. S9E ). Entry of 312 VSVDG-G, which requires low pH as a trigger for membrane fusion, was sensitive to all three 313 inhibitors in both cell lines (Figs. S9A and C). By contrast, VSVDG-PIV5 entry, which occurs by 314 fusion at the plasma membrane, was insensitive to any of the inhibitors (Figs. S9B and D) . 315 VSVDG-BHLD entry into C10 cells was inhibited by all three endosomal acidification 316 inhibitors (Fig. 7B ) and thus appears to require endosomal acidification. VSVDG-BHLD entry 317 into CHO-HVEM cells was inhibited only by one out of three inhibitors, NH 4 Cl (Fig. 7D) and 318 likely does not require endosomal acidification. Interestingly, HSV-1 entry into both C10 and 319 CHO-HVEM cells was inhibited by NH 4 Cl and monensin but not by BFLA (Figs. 7A and C) . 320

We hypothesize that the discrepancy in the inhibitory effects among the three inhibitors could 321 potentially be due to the distinct mechanisms by which BFLA, NH 4 Cl, and monensin raise 322 endosomal pH. 323 324

narrower tropism of VSVDG-BHLD pseudotype relative to HSV-1 suggested that envelope 326 proteins outside the essential four may contribute to HSV-1 tropism and entry efficiency. To test 327 this hypothesis, we generated a VSV-pseudotype containing gC in addition to gB, gH, gL, and 328 gD (VSVDG-BHLD-gC) (Fig. 8A) . To generate the VSVDG-BHLD-gC pseudotype at 329 sufficiently high titers suitable for entry experiments, the amount of gB plasmid transfected into 330

HEK293T cells was increased. The corresponding VSVDG-BHLD-pCAGGS control was 331 generated similarly. For yet unclear reasons, VSVDG-BHLD-pCAGGS entered CHO-nectin-1, 332 CHO-HVEM, and HaCaT cells (Fig. 8B ) more efficiently than the VSVDG-BHLD pseudotype 333 ( Fig. 1A) . Transfection of higher amounts of the gB plasmid could, in principle, lead to a higher 334 expression levels of gB in the cells and, consequently, higher incorporation into the virions. 335

More importantly, however, the VSVDG-BHLD-gC pseudotype entered CHO-HVEM and 336

HaCaT cells with a significantly higher efficiency than the VSVDG-BHLD-pCAGGS 337 pseudotype (Fig. 8B) . These results suggest that gC can increase cell entry efficiency in a cell-338 specific manner. 339 340

Decades ago, glycoproteins gB, gH, gL, and gD were established as essential for HSV-1 entry 342 (6-8). These four glycoproteins are also sufficient for cell-cell fusion when co-expressed in 343 uninfected, receptor-bearing cells (11, 12) . While these studies greatly increased our 344 understanding of the HSV-1 entry and fusion mechanisms, it was unclear whether these four 345 glycoproteins were sufficient to specify cellular tropism and the selection of entry routes, partly 346 due to the presence of up to 12 other envelope proteins. To begin addressing this, we generated a 347 VSV-based pseudotype containing HSV-1 gB, gH, gL, and gD. Being devoid of other HSV-1 348 proteins, the VSVDG-BHLD pseudotype provides a bare-bones platform to identify 349 contributions of the core set of four essential glycoproteins to HSV-1 cellular tropism and the 350 selection of entry routes. 351

Previously, we showed that the VSVDG-BHLD pseudotype efficiently entered C10 cells 352 and that its entry recapitulated several important features of HSV-1 entry into susceptible cells: 353 the requirement for gB, gH, gL, gD, and a gD receptor and sensitivity to anti-gB and anti-gH/gL 354 neutralizing antibodies (39). Here, we expanded this study to six additional HSV-1-susceptible 355 cell lines and made two key observations. First, we found that in addition to C10 cells, only 356 HSV-1 entered these two cell lines by distinct endocytic mechanisms as judged by the 358 differences in sensitivity to various inhibitors ( Fig. 9 and Table S1 ). These results imply that 359 alone, gB, gH, gL, and gD permit entry of VSV pseudotypes only into a limited range of HSV-1-360 susceptible cell types and even then, do not specify native entry routes. On the basis of these 361 results, we hypothesize that other HSV-1 envelope proteins may have underappreciated roles in 362 defining HSV-1 tropism, entry route selection, or both. Although it may be too early to conclude 363 that the incorporation of gC into the VSVDG-BHLD pseudotype has changed its tropism, the 364 increase in cell-specific entry efficiency of the VSVDG-BHLD-gC pseudotype supports the use 365 of the pseudotyping platform developed here for future gain-of-function studies. In these future 366 studies, changes in tropism, entry routes, or both, may be uncovered. 367 368 VSVDG-BHLD pseudotype has a narrower cellular tropism than HSV-1. HSV-1 can infect a 369 wide range of receptor-bearing cell types from different species [reviewed in (25) ]. However, the 370 VSVDG-BHLD pseudotype has a narrower tropism, efficiently entering only 2 out of 7 tested 371 cell lines. Puzzlingly, while VSVDG-BHLD entered two engineered rodent cell lines, it exhibited 372 little to no entry into the four human and primate cell lines typically used in HSV-1 studies, even 373 at an MOI of 10. The lack of VSVDG-BHLD entry did not correlate with the HSV-1 entry route 374 into these cells, namely, endocytosis for HeLa and HaCaT (5, 46) vs. plasma membrane for Vero 375 and SH-SY5Y (5, 44). Additionally, there was no clear correlation with the receptor type (nectin-376 1 vs. HVEM) or with the cell type. While any of these factors -species, cell type, receptor, or 377 route of entry -could potentially account for the decreased entry efficiency observed for 378 VSVDG-BHLD pseudotype, none stood out as major infectivity determinants. 379

We do not yet fully understand the reasons for the observed differences in tropism 380 between the VSVDG-BHLD pseudotype and HSV-1. At a first glance, the differences in virion 381 structure -bullet-shaped vs. spherical -could be responsible for the phenotypic differences. 382

However, the apparent differences in the entry of VSVDG-BHLD, VSVDG-G, and VSVDG-383 PIV5 pseudotypes, all of which share the same VSV structure, suggest that virion structure is 384 unlikely to be a major factor responsible for the observed differences in entry of VSVDG-BHLD 385 and HSV-1. The gB:gH:gL:gD ratios were also similar between VSVDG-BHLD and HSV-1. The 386 two viruses could, however, differ in lipid composition because VSV and HSV-1 acquire their 387 envelopes from different sources. VSV buds at the plasma membrane (PM) (27) This leaves differences in glycoprotein content as a potential reason for the differences in 402 tropism. HSV-1 has up to 12 envelope proteins outside of the core set of four, which are absent 403 from VSVDG-BHLD. We hypothesize that efficient entry by HSV-1 into susceptible cells 404 requires one or more of these other proteins. Indeed, some of them have already been shown to 405 increase HSV-1 entry efficiency. For example, deletion of the N terminus of glycoprotein K (gK) 406 promoted inefficient endocytic entry into Vero cells (85, 86), which normally support entry by 407 fusion at the plasma membrane (44). The N terminus of gK may thus regulate the fusion of the 408 viral envelope with the plasma membrane (85). Another HSV-1 glycoprotein, gC, aids viral 409 attachment by binding heparan sulfate moieties of cell surface proteoglycans (87) and promotes 410 efficient entry into cells that HSV-1 enters by an endocytic route (88). Thus, envelope proteins 411 outside of the core set of four could, indeed, modulate HSV-1 tropism by tuning entry efficiency. 412

In other words, the more efficiently HSV-1 enters a given cell type, the more likely that cell type 413 is to be successfully infected. 414

This hypothesis could be tested by adding the "non-essential" envelope proteins one-by-415 one into the VSVDG-BHLD pseudotype to test for their ability to restore entry into specific cell 416 lines. For example, the incorporation of gK into the VSVDG-BHLD pseudotype (VSVDG-417 BHLD-gK) would be expected to increase the entry efficiency into cells that HSV-1 enters by 418 fusion at the plasma membrane (Vero and SH-SY5Y), whereas gC (VSVDG-BHLD-gC) could 419 increase the entry efficiency into cells that HSV-1 enters by endocytosis (C10, CHO-nectin-1, 420 CHO-HVEM, HeLa and HaCaT). Indeed, we found that incorporating gC into the VSVDG-421 BHLD pseudotype increased entry efficiency into CHO-HVEM and HaCaT cells. These results 422 are consistent with the reduced entry efficiency of an HSV-1 mutant lacking gC into these cell 423 types (88). The mechanism underlying the gC-dependent gain-of-function phenotype of 424 VSVDG-BHLD-gC will be explored in future work. 425 426 VSVDG-BHLD pseudotype is internalized differently from HSV-1. If HSV-1 gB, gH, gL, and 427 gD were sufficient to specify the native routes of HSV-1 entry, then we would have expected the 428 VSVDG-BHLD pseudotype to utilize the same entry routes into C10 and CHO-HVEM as HSV-429 1. However, while entry of both viruses occurred by endocytosis and required dynamin and 430 cellular cholesterol but not caveolin-1 or actin polymerization, further investigation uncovered 431 several notable differences in entry requirements ( Fig. 9 ). 432

The first difference was that HSV-1 entry into C10 or CHO-HVEM cells was inhibited 433 by the clathrin inhibitor Pitstop-2, suggesting that it occurred by CME, whereas VSVDG-BHLD 434 entry was not. HSV-1 entry inhibition by Pitstop-2 was unexpected because HSV-1 does not 435 appear to utilize clathrin for entry into several cell lines, including HaCaT (89), CHO-nectin-1 436 (90), Vero, HeLaS3, and HeLaCNX cells (91). However, the role of clathrin in entry into C10 or 437 CHO-HVEM cells had not been assessed prior to this study. Moreover, recent work has 438 suggested that HSV-1 entry into a human oligodendrocytic cell line (HOG) depends on clathrin 439 (92). Therefore, HSV-1 may utilize CME in a cell-specific manner. 440

Unlike HSV-1 entry, VSVDG-BHLD entry into C10 or CHO-HVEM cells was not 441 inhibited by Pitstop-2, which implicated CIE, rather than CME, as the entry route. 442

Macropinocytosis is a common CIE used by several viruses, but VSVDG-BHLD entry into both 443 C10 and CHO-HVEM cells was insensitive to the inhibitor of actin polymerization, cytochalasin 444 D, as was HSV-1. Given the essential role of actin polymerization in macropinocytosis (68, 71), 445 these data suggest that macropinocytosis is not the primary entry mechanism for VSVDG-BHLD 446 pseudotype or HSV-1. Accordingly, VSVDG-BHLD particles did not colocalize with a fluid 447 phase uptake marker 70 kDa rhodamine-B-labeled dextran to an appreciable extent. The lack of 448 actin involvement in HSV-1 entry was not entirely surprising because its requirement, as deemed 449 by cytochalasin D treatment, varies from cell line to cell line. For example, cytochalasin D 450 treatment blocked entry into CHO-nectin-1 cells (90) (79)]. In contrast, Arf6 was dispensable for VSVDG-BHLD entry. 476

One notable difference between VSVDG-BHLD and HSV-1 entry into C10 cells was that 477 VSVDG-BHLD entry required endosomal acidification. Previous work suggested that HSV-1 478 entry into C10 cells did not require endosomal acidification (45). Indeed, we confirmed that 479 HSV-1 entry into C10 cells was insensitive to bafilomycin A1 (BFLA), a well-known inhibitor 480 of endosomal acidification. The requirement for endosomal acidification for VSVDG-BHLD 481 entry into C10 cells was unexpected. The membrane fusion itself may not require low pH, in 482 agreement with the observations that cell-cell fusion in the presence of gB, gH, gL, and gD 483 occurs at neutral pH (13). However, concomitant with the endosomal acidification, there are 484 significant changes in endosomal ion concentrations and lipid content (97), which could affect 485 membrane fusion or the fusion pore expansion. Therefore, we hypothesize that during VSVΔG-486 BHLD entry, endosomal acidification promotes the establishment of endosomal conditions 487 conducive to fusion and that in HSV-1, envelope proteins outside the essential four may 488 functionally replace endosomal acidification. 489

Surprisingly, HSV-1 entry into both C10 and CHO-HVEM cells was inhibited by two 490 other inhibitors of endosomal acidification, NH 4 Cl and monensin. Previous work showed that 491 HSV-1 entry into CHO-HVEM cells was sensitive to inhibitors of endosomal acidification 492 ammonium chloride (NH 4 Cl) and monensin (46, 98), indicating a requirement for endosomal 493 acidification. While NH 4 Cl and monensin alkalinize the lumen of endosomes, the mechanisms 494 by which they do so differ dramatically from BFLA. NH 4 Cl, when dissolved, exists in 495 equilibrium as NH 3 and NH 4 + . Upon entering acidic environment, e.g., an endosome, NH 3 496 becomes protonated to NH 4 + , which leads to an increase in endosomal pH (97). Monensin is a 497 carboxylic ionophore that utilizes an electroneutral exchange of monovalent cations for protons, 498 effectively raising the endosomal pH (97). In parallel to these alkalinizing effects, NH 4 Cl and 499 monensin can affect other cellular processes, e.g., vacuolization or organelle swelling. In 500 contrast, BFLA functions by specifically blocking the function of the V 0 domain of V-ATPases 501 thereby blocking the movement of protons across the endosomal membrane (99). At the nM 502 concentrations used, BFLA is very specific and potent in its action. Therefore, given that HSV-1 503 entry into either C10 or CHO-HVEM cells was not blocked by BFLA, we hypothesize that it 504 does not require endosomal acidification. Sensitivity of HSV-1 entry to NH 4 Cl and monensin 505 could, instead, be due to their ability to interfere with other cellular processes. Both compounds 506 alter ion content of the endosomes and cause vacuolization (97). While the impact of endosome 507 vacuolization on HSV-1 entry has not been investigated, a change in endosomal ion 508 concentration could, potentially, reduce the ability of HSV-1 to fuse with the endosomal 509 membrane. Indeed, binding of HSV-1 to the cell surface releases intracellular Ca 2+ stores (100) 510 and increases intracellular levels of Clions (101), both of which appear important for 511 subsequent entry. 512

Collectively, we hypothesize that HSV-1, which does not require Rab5/7 or endosomal 513 acidification, fuses with the endosomal membrane prior to maturation of the newly formed 514 vesicle into an early endosome [pH ~6.2 (102)] (Fig. 9 ). This latter scenario is consistent with 515 the rapid nature of HSV-1 entry into both C10 and B78A10 cells (B78 murine melanoma cells 516 expressing HVEM) cells (t 1/2 = 8-10 minutes) (45). Alternatively, endosomal maturation status 517 does not influence HSV-1 fusion with the membrane of the endocytic vesicle. VSVDG-BHLD 518 entry into CHO-HVEM cells, likewise, does not require Rab5/7 or endosomal acidification, 519

implying that VSVDG-BHLD may fuse with the endosomal membrane prior to delivery of the 520 endocytic vesicle to an early endosome. By contrast, VSVDG-BHLD entry into C10 cells 521 requires both Rab5 and endosomal acidification, which suggests that VSVDG-BHLD fuses with 522 membranes of early endosomes. This would suggest that during HSV-1 entry into C10 cells, 523 other envelope proteins may enable fusion prior to endosomal acidification. 524

As this and other studies show, HSV-1 entry is a complex phenomenon that requires at 525 least four glycoproteins (gB, gH, gL, and gD) that operate in the presence of up to 12 additional 526 envelope proteins, understudied with regard to entry. By establishing a platform where the 527 functionality of the four essential HSV-1 entry glycoproteins could be evaluated in isolation, we 528 demonstrated that they are insufficient to define HSV-1 tropism or specify native entry routes. 529

We have expanded the use of this platform by demonstrating that incorporation of an additional 530 envelope protein, gC, can lead to increased entry. Collectively, our work implicates other HSV-1 531 envelope proteins as underappreciated, yet potentially important contributors to HSV-1 tropism, 532 entry route selection, and, ultimately, pathogenesis. Plasmids. Plasmids pPEP98, pPEP99, pPEP100, and pPEP101 carry the full-length HSV-1 559 (strain KOS) genes for gB, gD, gH, and gL, respectively in a pCAGGS vector background. 560 These were kindly gifted by P.G. Spear (Northwestern University). pCMV-VSV-G, which 561 contains the full-length gene for the VSV glycoprotein, G, was a gift from Judith White 562

and dsRed-Rab7DN] were purchased from Addgene (76, 77). For consistency, the dsRed in 564 dsRed-Rab7DN was replaced with mCherry by amplifying mCherry with the following primers: 565 5'-AGCGCTACCGGTCGCCACCATGGTGAGCAAGGGCGAG-3' (forward) and 5'-566 AATTCGAAGCTTGAGCTCGAGATCTGAGCTTGTACAGCTCGTCCATGCC-3' (reverse). 567 mCherry was then cloned in frame with Rab7DN using AgeI and HindIII cut sites that were 568 engineered into the forward and reverse primers, respectively. As our HSV-1 reporter strain uses 569 tdTomato, eGFP-RabDN constructs were engineered. The same primers were used to amplify 570 eGFP from pEGFP-N2. The same cloning procedure was used to replace mCherry and dsRed 571 with eGFP in the Rab5DN and Rab7DN constructs, respectively. Isolated clones were sequenced 572 to verify mCherry and eGFP were in frame with the DN Rab genes. HSV-1 gC was amplified 573 from HSV-1 (F strain) BAC DNA (GS6000) with the following primers: 5'-574 CGAGCTCGGCCACCATGGCCCCGGGGCGGG-3' (forward) and 5'-575 GGGGTACCCCTCACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCC 576 CGCCGATGACGCTGCCG-3' (reverse). The amplicon was digested with SacI and KpnI and 577 cloned into the expression vector, pCAGGS. The C-terminus of gC was tagged with a V5 578 epitope tag for western blot purposes. 579 580 Antibodies. Nectin-1 antibody [clone CK41 (103)] conjugated to phycoerythrin (PE) was 581 purchased from BD Biosciences. PE-isotype antibody was also purchased from BD Biosciences. 582 HVEM antibody (R140) was a gift from Gary Cohen (University of Pennsylvania). Caveolin-1 583 antibody (clone 4H312) was purchased from Santa Cruz Biotechnology. b-actin antibody 584 conjugated to horse radish peroxidase(sc-47778 HRP) was purchased from Santa Cruz 585

Biotechnology. Anti-V5 antibody (V8137) was purchased from Sigma-Aldrich. 586 587 Chemical inhibitors. Monensin, methyl-b-cyclodextrin, cytochalasin D, Pitstop-2, and EIPA 588 were purchased from Sigma. Dynasore and MiTMAB were purchased from Calbiochem. 589

Bafilomycin A1 was purchased from ApexBio. Ammonium chloride was purchased from Fisher 590 Scientific. Dyngo-4a was purchased from Abcam. NSC23766 was purchased from Santa Cruz 591

Biotechnology. 592 593 Viruses. Pseudotyped viral particles (VSVDG-BHLD) were generated as described previously 594 (39). Briefly, HEK293T cells (5.5 x 10 6 cells/10 cm dish) were transfected with 2.5 µg each 595 pPEP98, pPEP99, pPEP100, and pPEP101 using polyethyleneimine (PEI at 1 mg/ml) at a 3:1 596 weight ratio of PEI to DNA. VSVDG-BHLD-pCAGGS and VSVDG-BHLD-gC were generated 597 by transfecting HEK293T cells with 10 µg pPEP98 and 2.5 µg each of pPEP99, pPEP100, 598 pPEP101, and pCAGGS or pCAGGS-gC-V5 using GenJet Ver. II (SignaGen Laboratories). In 599 all cases, 24 hours post transfection, cells were infected at an MOI = 3 with VSVDG-G (VSVDG 600 pseudotyped with VSV G protein) and incubated at 30° C. Forty-eight hours post infection, 601 supernatants were collected, cleared of cell debris (two spins at 1500 x g for 10 minutes each), 602 and stored at -80° C. VSVDG-BHLD, VSVDG-BHLD-pCAGGS, and VSVDG-BHLD-gC titers 603 were determined on C10 cells. 604 HSV-1 (GS3217, F strain) was kindly provided by Gregory Smith (Northwestern 605 University). GS3217 contains a tdTomato reporter gene with a nuclear localization signal under 606 control of a CMV immediate early (IE) promoter (104). HSV-1 was propagated on Vero cells, 607 and titers were determined by plaque assay on Vero cells as previously described (105). 608 VSVDG-G helper virus was generated by Michael Whitt (University of Tennessee) and kindly 609 provided by Judith White (University of Virginia). New stocks were generated similarly to the 610 VSVDG-BHLD pseudotypes, replacing the HSV-1 glycoproteins with pCMV-VSV-G (10 µg per 611 10 cm dish). VSVDG-G titers were determined on C10 cells. VSVDG-PIV5 was generated and 612 kindly provided by S.P.J. Whelan (Washington University). As VSVDG-PIV5 contains the PIV5 613 pelleted at 20,0000 RPM. Western blots for gB, gH, gL, and gD were done using the rabbit 671 polyclonal R68 antibody (gB), the rabbit polyclonal R137 antibody (gH), the mouse monoclonal 672 antibody L1 (gL), and the rabbit polyclonal antibody R7 (gD). Secondary antibodies from LI-673 COR were used in order to perform densitometry analysis using the Image Studio Lite software 674 (IRDye ® 680RD goat anti-rabbit and IRDye ® 800CW goat anti-mouse). Raw densitometry 31 values for gH, gL, and gD blots were normalized to their respective raw densitometry values for 676 gB and reported as fold-differences to gB. incubated with 1 mg/ml 70 kDa dextran and VSVDG-BHLD (MOI = 1) for 1 hour at 4° C to 696 allow for virion attachment. Cells were then shifted to 37° C for 20 minutes. After 20 minutes, 697 cells were prepared for confocal microscopy by fixing with 4% paraformaldehyde, permeabilized 698 and blocked with 1X PBS containing 5% normal goat serum and 0.3% Triton X-100. Cells were 699 then incubated with anti-gB antibody (R68) overnight at 4° C. The next day, cells were incubated 700 with a secondary antibody labeled with FITC for 1 hour at room temperature. Slides were then 701 prepared as described above. Chowdary TK, Cairns TM, Atanasiu D, Cohen GH, Eisenberg RJ, Heldwein EE. 2010. 794 Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. HaCaT, and SH-SY5Y. Cells were infected at a MOI of 1. Entry was quantitated by flow cytometry at 6 hours post infection. C) Cell surface expression of nectin-1 (C) and HVEM (D) was analyzed by flow cytometry. Surface levels of nectin-1 were quantitated by staining cells with an anti-nectin-1 monoclonal antibody CK41 conjugated to phycoerythrin (PE) (green histograms). Surface levels of HVEM were quantitated by staining cells with an anti-HVEM polyclonal antibody R140 and a FITClabeled secondary antibody (cyan). Blue histograms are isotype controls. Red histograms are mock (no antibody) controls. E&F) Relative ratios of gB:gH:gL:gD for HSV-1 and VSVΔG-BHLD particles. HSV-1 and VSVΔG-BHLD virions were purified either through a continuous sucrose gradient (HSV-1) or continuous Optiprep gradient (VSVΔG-BHLD), pelleted, and analyzed for their glycoprotein content (gB, gH, gL, and gD) by Western blot (anti-gB pAb R68, anti-gH pAb = R137, anti-gL mAb L1, and anti-gD pAb R7). A representative Western blot is shown. The amounts of gB, gH, gL, and gD in three different virion preparations were determined by densitometry. Levels of gH, gL, and gD were normalized to gB levels from their respective virions. A Student's T-test with Welch's correction was used to determine the significance of differences between relative amounts of gH, gL, or gD between HSV-1 and VSVΔG-BHLD virions (ns = not significant; p < 0.05 = *; p < 0.01 = **; p < 0.001 = ***). and VSVΔG-BHLD at MOI = 1. Infectivity was quantitated by flow cytometry at 6 hours post infection. Significance was calculated using a two-tailed Student's T-test with Welch's correction (p < 0.05 = *; p < 0.01 = **; p < 0.001 = ***). Fig. 3 . Both HSV-1 and VSVΔG-BHLD require dynamin but only HSV-1 requires clathrin for entry . C10 (A and C) and CHO-HVEM (B and D) cells were pretreated with dynamin inhibitors Dynasore (80 µM), Dyngo-4a (25 µM), MiTMAB (5 µM), or the CME inhibitor, Pitstop-2 (30 µM) and infected with HSV-1 or VSVΔG-BHLD at MOI = 1. Infectivity was quantitated by flow cytometry at 6 hours post infection. CHO-HVEM cells treated with Dyngo-4a or MiTMAB used the same DMSO control, as indicated by the same bar graph appearing twice each in panels C and D. Significance was calculated using a two-tailed Student's T-test with Welch's correction (p < 0.05 = *; p < 0.01 = **; p < 0.001 = ***). ) and CHO-HVEM (C and D) cells were pretreated with a cholesterol-removal drug methyl-βcyclodextran, MβCD (5 mM) and infected with HSV-1 (A and C) or VSVΔG-BHLD (B and D) at MOI = 1. Infectivity was quantitated by flow cytometry at 6 hours post infection. E) CHO-HVEM cells were transfected with a caveolin-1 siRNA (cav-1) or a scrambled control siRNA (scr) (both 50 pm) and infected with HSV-1 or VSVΔG-BHLD at MOI = 1. Infectivity was quantitated by flow cytometry at 6 hours post infection. Significance was calculated using a two-tailed Student's T-test with Welch's correction (p < 0.05 = *; p < 0.01 = **; p < 0.001 = ***). F) Western blot analyses, using antibody clone 4H312 (Santa Cruz Biotechnology), of caveolin-1 knockdown in CHO-HVEM cells (representative of three western blots, one from each biological replicate). G) Western blot analyses, using antibody clone 4H312 (Santa Cruz Biotechnology), of caveolin-1 levels in C10, CHO-HVEM, and 3T12 cells.

A C10 B ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ ✱ p=0.0775 HSV-1 ✱ ✱ ✱ ✱ CHO-HVEM C10 C D VSVΔG-BHLD

A B and infected with either HSV-1 or VSVΔG-BHLD at an MOI = 1. Significance was calculated using a two-tailed Student's T-test with Welch's correction (ns = not significant; p < 0.05 = *; p < 0.01 = **; p < 0.001 = ***).

A B Significance was calculated using a two-tailed Student's T-test with Welch's correction (p < 0.05 = *; p < 0.01 = **; p < 0.001 = ***). 

Update on herpes virus infections of the nervous system

Seroprevalence of herpes 740 simplex virus types 1 and 2--United States

Cell entry mechanisms of HSV: what we have learned in 742 recent years

Infection and 744 Transport of Herpes Simplex Virus Type 1 in Neurons: Role of the Cytoskeleton

Herpes simplex virus type 1 enters human 747 epidermal keratinocytes, but not neurons, via a pH-dependent endocytic pathway

Role of glycoprotein B of herpes simplex virus type 1 in 750 viral entry and cell fusion

A mutant herpes simplex virus type 1 unable 752 to express glycoprotein L cannot enter cells, and its particles lack glycoprotein H

A herpes simplex virus mutant in which glycoprotein D 755 sequences are replaced by beta-galactosidase sequences binds to but is unable to 756 penetrate into cells

Entry of herpesviruses into mammalian cells

Fusing structure and 760 function: a structural view of the herpesvirus entry machinery

Characterization of cell-cell fusion mediated by herpes simplex 763 virus 2 glycoproteins gB, gD, gH and gL in transfected cells

Glycoproteins gB, gD, and gHgL of 765 herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a 766 Cos cell transfection system

Cascade of events governing cell-768 cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB

Herpes virus fusion and entry: a story with many characters

Three classes of cell surface receptors for 773 alphaherpesvirus entry

Structure of unliganded HSV gD reveals a 776 mechanism for receptor-mediated activation of virus entry

Engineered disulfide bonds in herpes simplex virus type 1 gD separate receptor 779 binding from fusion initiation and viral entry

Cohen 781 GH. 2019. Surface Plasmon Resonance Reveals Direct Binding of Herpes Simplex Virus

Glycoproteins gH/gL to gD and Locates a gH/gL Binding Site on gD

784 Regulation of Herpes Simplex Virus gB-Induced Cell-Cell Fusion by Mutant Forms of 785 gH/gL in the Absence of gD and Cellular Receptors

Herpes simplex virus gD forms 787 distinct complexes with fusion executors gB and gH/gL in part through the C-terminal 788 profusion domain

Bimolecular complementation defines functional regions of Herpes simplex virus 791 gB that are involved with gH/gL as a necessary step leading to cell fusion

Herpes simplex 976 virus internalization into epithelial cells requires Na+/H+ exchangers and p21-activated 977 kinases but neither clathrin-nor caveolin-mediated endocytosis

Hsv-1 Endocytic Entry into a 979

Human Oligodendrocytic Cell Line is Mediated by Clathrin and Dynamin but Not 980 Caveolin. Viruses 12. 981 93

Effects of Na+/H+ exchanger inhibitors on subcellular 986 localisation of endocytic organelles and intracellular dynamics of protein transduction 987 domains HIV-TAT peptide and octaarginine

989 Inhibition of Na+-H+ exchange impairs receptor-mediated albumin endocytosis in renal 990 proximal tubule-derived epithelial cells from opossum

Coordination between Rac1 and Rab Proteins: Functional 992 Implications in Health and Disease. Cells 8

Endosome maturation

Entry of herpes simplex virus mediated 995 by chimeric forms of nectin1 retargeted to endosomes or to lipid rafts occurs through 996 acidic endosomes

Proton conduction and bafilomycin binding by the V0 998 domain of the coated vesicle V-ATPase

Herpes simplex viruses activate phospholipid 1000 scramblase to redistribute phosphatidylserines and Akt to the outer leaflet of the plasma 1001 membrane and promote viral entry

1003 Inhibition of herpes simplex virus type 1 entry by chloride channel inhibitors tamoxifen 1004 and NPPB

Endosome maturation, transport and functions

The Herpes Simplex Virus 1 Deamidase Enhances 1010 Propagation but Is Dispensable for Retrograde Axonal Transport into the Nervous 1011 System

Herpes simplex virus growth, preparation, and assay

Purification of Herpesvirus Virions and Capsids

Smac mimetics and oncolytic viruses synergize in driving anticancer 1018 T-cell responses through complementary mechanisms

Tani VSVΔG-PIV5 at an MOI = 1. Significance was calculated using a two-tailed Student's T-test 1208 with Welch's correction (ns = not significant; p < 0.05 = *; p < 0.01 = **; p < 0.001 = ***).